Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2012
09/13/2012US20120232009 Methods for Treatment of Insulin-Like Growth Factor-1 Deficiency
09/13/2012US20120232008 Plgf-1 in homodimeric form
09/13/2012US20120232007 Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
09/13/2012US20120232006 Production of polyurethane foams
09/13/2012US20120232005 Lipoprotein complexes and manufacturing and uses thereof
09/13/2012US20120232004 Methods for Treating Autoimmune Disorders, and Reagents Related Thereto
09/13/2012US20120232003 Compositions and methods for diabetes treatment
09/13/2012US20120232002 Slow-acting insulin preparations
09/13/2012US20120232001 Stable formulations for parenteral injection of peptide drugs
09/13/2012US20120232000 Methods and compositions for promoting regeneration by increasing intracellular sodium concentration
09/13/2012US20120231999 Peptidic glp-2 agonists
09/13/2012US20120231998 Organic compounds and their uses
09/13/2012US20120231997 Recombinant human cc10 protein for treatment of influenza
09/13/2012US20120231996 Phalloidin derivatives and methods for their synthesis
09/13/2012US20120231995 Use of pyrroloquinoline compounds to kill clinically latent microorganisms
09/13/2012US20120231994 Antagonism of human formyl peptide receptor for treatment of disease
09/13/2012US20120231993 NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ALPHA-AMINO BORONIC ACID DERIVATIVES via SUBSTITUTED ALK-1-YNES
09/13/2012US20120231093 Method for preparing nano-scale or amorphous particle using solid fat as a solvent
09/13/2012US20120231091 Method for Inducing Differentiation of Dental Pulp Cells Into Odontoblasts
09/13/2012US20120231087 Compositions And Methods for Nutritional Supplementation
09/13/2012US20120231071 Natural product inhibitors of 3dg
09/13/2012US20120231067 Vesicle compositions
09/13/2012US20120231065 Methods of treating neurological conditions with hematopoeitic growth factors
09/13/2012US20120231040 Cysteine variants of interleukin-11 and methods of use thereof
09/13/2012US20120231038 Wound Healing Compositions Comprising Biocompatible Cellulose Hydrogel Membranes and Methods of Use Thereof
09/13/2012US20120231036 Cloned biological material medical device and method thereof
09/13/2012US20120231022 Glp-1 receptor agonist compounds for sleep enhancement
09/13/2012US20120231014 Neural Regeneration
09/13/2012US20120231013 Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
09/13/2012US20120231010 Vinpocetine and eburn amonine derivatives for promoting bone growth
09/13/2012US20120231007 Modulators of cell cycle progression
09/13/2012US20120231003 Ox2 Receptor Homologs
09/13/2012US20120231002 Treatment of vasculoproliferative conditions
09/13/2012US20120230997 Anti-factor B antibodies and their uses
09/13/2012US20120230995 Polyspecific binding molecules and uses thereof
09/13/2012US20120230994 Bladder cancer specific ligand peptides
09/13/2012US20120230992 Vegf-related protein
09/13/2012US20120230979 NOGO Receptor Binding Protein
09/13/2012US20120230977 Flowable collagen-based hemostat and methods of use
09/13/2012US20120230976 Rothia species glutamine endopeptidases and use thereof
09/13/2012US20120230975 Fusion proteins
09/13/2012US20120230974 Alkaline alpha galactosidase for the treatment of fabry disease
09/13/2012US20120230973 Lactase preparation
09/13/2012US20120230972 Salinosporamides and Methods for Use Thereof
09/13/2012US20120230971 Chromosomal modification involving the induction of double-stranded dna cleavage and homologous recombination at the cleavage site
09/13/2012US20120230970 Method for treating pervasive development disorders
09/13/2012US20120230965 Novel Microorganism Bacillus megaterium Toha Producing L-Type Poly-Gamma-Glutamic Acid and L-Type Poly-Gamma-Glutamic Acid Produced Thereby
09/13/2012US20120230962 Gp100-specific t cell receptors and related materials and methods of use
09/13/2012US20120230955 Arabinoxylans for modulating the barrier function of the intestinal surface
09/13/2012US20120230954 Drug Comprising As The Active Ingredient Proliferative Vector Containing Survivin Promoter
09/13/2012US20120230953 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
09/13/2012US20120230952 Detection of bladder cancer
09/13/2012US20120230951 Antiviral compounds
09/13/2012US20120230950 Compositions and Methods for Soft Tissue Augmentation
09/13/2012US20120230949 Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide
09/13/2012US20120230948 Brachyury polypeptides and methods for use
09/13/2012US20120230947 Biologically active proteins having increased in vivo and/or in vitro stability
09/13/2012US20120230946 Fusion molecules and il-15 variants
09/13/2012US20120230945 Targeted particles and methods of using the same
09/13/2012US20120230944 Stabilization and storage of biological pharmaceutical compositions
09/13/2012US20120230943 Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
09/13/2012US20120230942 GEP, a novel chondrogenic growth factor and target in cartilage disorders
09/13/2012US20120230941 Methods for treating nervous system injury and disease
09/13/2012US20120230940 Conditioned cell culture medium compositions and methods of use
09/13/2012US20120230939 Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
09/13/2012US20120230930 Methods For Activating Caspase-14 Expression In Human Skin
09/13/2012US20120230926 Method For Cosmetically Treating Caspase-14 Deficiency
09/13/2012DE102011013326A1 Neue Fibrinolyse-Inhibitoren und deren mdizinische Verwendung New fibrinolysis inhibitors and their use mdizinische
09/13/2012DE102011005288A1 Producing protein hydrolyzate, useful as angiotensin converting enzyme inhibitor, comprises enzymatically hydrolyzing protein containing substrate in two treatment steps with different proteolytic enzymes
09/13/2012CA2834990A1 Treatment of disorders with altered vascular barrier function
09/13/2012CA2829858A1 Methods for diagnosing and/or treating sterility
09/13/2012CA2829400A1 Stable formulations for parenteral injection of peptide drugs
09/13/2012CA2829363A1 Helium charged refrigerator
09/13/2012CA2829128A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/13/2012CA2829037A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
09/13/2012CA2829006A1 Locally released growth factors to mediate motor recovery after stroke
09/13/2012CA2828966A1 Peptide linkers for polypeptide compositions and methods for using same
09/13/2012CA2828940A1 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
09/13/2012CA2828889A1 Hydrogen bond surrogate macrocycles as modulators of ras
09/13/2012CA2828411A1 Vectors conditionally expressing protein
09/13/2012CA2828343A1 Edn3-like peptides and uses thereof
09/13/2012CA2827662A1 Active agent prodrugs with heterocyclic linkers
09/13/2012CA2827368A1 Skin-beautifying agent
09/12/2012EP2497784A1 Peptide capable of promoting cell proliferation, and use thereof
09/12/2012EP2497780A1 TDF-related compounds and analogs thereof
09/12/2012EP2497777A2 Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
09/12/2012EP2497490A1 Methods for diagnosing and/or treating sterility
09/12/2012EP2497489A1 Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/12/2012EP2497488A1 Method for treating delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA
09/12/2012EP2497487A1 Method for treating diabetes and atherosclerosis associated with changes of qualitative and/quantitative composition of blood extracellular DNA
09/12/2012EP2497486A1 Method for treating diseases caused by fungi associated with changes of qualitative and/quantitative composition of blood extracellular DNA
09/12/2012EP2497485A1 Compound and method for regulating plasminogen activation and cell migration
09/12/2012EP2497484A2 A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
09/12/2012EP2497462A1 Stable non-aqueous pharmaceutical compositions
09/12/2012EP2496691A2 Therapeutic nuclease compositions and methods
09/12/2012EP2496607A2 Vault complexes for cytokine delivery
09/12/2012EP2496596A1 Therapeutic peptides
09/12/2012EP2496273A2 Purified emd protein composition
09/12/2012EP2496268A1 Nanoparticle-based gene delivery systems
09/12/2012EP2496267A2 Zwitterionic polymer bioconjugates and related methods
1 ... 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 ... 3163